Macitentan CAS 441798-33-0

1. Macitentan is an orally active dual endothelin receptor antagonist (ERA) that blocks the binding of endothelin-1 (ET-1) to both ETA and ETB receptors, thereby reducing vasoconstriction, fibrosis, proliferation, and inflammation in patients with pulmonary arterial hypertension (PAH) .
2. Macitentan CAS 441798-33-0 is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression, which includes reducing the risk of death, hospitalization for PAH, clinical worsening, and the need for parenteral prostanoid therapy .
3. Macitentan is metabolized in the liver via the CYP3A4 enzyme into a major pharmacologically active metabolite, ACT-132577, which contributes to its sustained therapeutic effect with a longer half-life (approximately 48 hours) than the parent drug .
4. In preclinical research, Macitentan CAS 441798-33-0 has demonstrated tissue-targeting properties due to its high lipophilicity, protecting against end-organ damage (such as renal vascular hypertrophy) in diabetic models and improving survival in pulmonary hypertensive rats .

1. Macitentan must be stored in a tightly sealed container at room temperature (below 30°C), protected from light and moisture, and kept away from direct sunlight and heat sources .
2. For long-term stability, Macitentan CAS 441798-33-0 powder is stable for up to 3 years at -20°C or 2 years at 4°C; stock solutions in solvent should be stored at -20°C for up to 1 month or at -80°C for up to 6 months, avoiding repeated freeze-thaw cycles .
3. Macitentan is classified as a hazardous substance with potential teratogenic effects; it is toxic if swallowed, a moderate to severe irritant to skin and eyes, and may cause serious eye damage (R41) . Personnel handling Macitentan must wear chemical-resistant rubber gloves, NIOSH/MSHA-approved respirators, and chemical safety goggles with side-shields .
4. Macitentan CAS 441798-33-0 is a pharmaceutically active ingredient that should only be handled by trained personnel familiar with potent active pharmaceutical ingredients; it should be kept away from incompatible materials such as strong oxidizing agents, strong acids, and strong bases to prevent decomposition .

1. Isolate the spill area, ensure adequate ventilation, and wear full personal protective equipment including chemical-resistant rubber gloves, chemical safety goggles, and NIOSH/MSHA-approved respirator when Macitentan is released .
2. Collect Macitentan CAS 441798-33-0 by sweeping or vacuuming without creating dust using non-sparking tools; for solutions, absorb with finely-powdered liquid-binding materials such as diatomite or universal binders .
3. Avoid creating dust clouds during cleanup to prevent respiratory exposure; decontaminate surfaces and equipment by scrubbing with alcohol, and prevent Macitentan from entering drains or water courses .
4. Dispose of collected material as hazardous waste according to local, state, and federal environmental regulations; Macitentan is considered non-hazardous for transport (DOT, IATA, IMDG) but requires proper waste management .

1. Macitentan is not classified as highly flammable but may decompose under fire conditions, emitting toxic fumes including carbon monoxide, carbon dioxide, and nitrogen oxides (NOx) .
2. Use water spray, dry chemical powder, carbon dioxide, or alcohol-resistant foam to extinguish fires involving Macitentan; do NOT use a direct water jet as Macitentan CAS 441798-33-0 may scatter burning material .
3. Firefighters should wear self-contained breathing apparatus in pressure-demand, MSHA/NIOSH approved, and full protective gear when handling burning Macitentan due to hazardous decomposition gases generated by thermal decomposition .
4. During combustion, Macitentan may emit irritant and toxic fumes; contain fire runoff to prevent environmental contamination and avoid release into waterways .